Details
Category: Volume 07 Issue 01 January 2019
Hits: 954

Title: Prevalence of androgen receptor positivity in triple negative breast cancers: clinico-pathological significance

Authors: Debahuti Mohapatra, Debasmita Das, Pranita Mohanty, Rajashree Tripathy

 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.142

Abstract

A unique subgroup of breast cancer, the Triple negative breast carcinoma (TNBC) is on rising trend. TNBC occurrence is around 15%-20% of all breast cancers. They are defined by absence of target therapy and prognostically worse as far as size, morphology, grading and staging are concerned. Thus, recent advent of androgen receptor (AR) sensitive target in some of the TNBC, which though are prognostically bad but has initiated target therapy successfully but still is under study. It is a sign of optimism for the oncologist for the treatment of incurable types of TNBCs. A study was done at IMS and SUM hospital, Bhubaneswar on 110 cases of breast carcinoma, among which 24 cases were TNBC. These included high grade infiltrating duct carcinoma (IDC-NST), metaplastic carcinomas, medullary carcinomas, neuro-endocrine carcinoma, apocrine carcinoma and acinic cell carcinoma. The tumors were designated as triple negative based on ER, PR, HER 2/neu staining. The proliferative index (Ki-67) and as well as AR staining were additional done, which showed 16.66% cases of AR positivity and most of which showed high proliferative index more than 21%.

Keywords: TNBC, Androgen receptor, Breast carcinoma.

References

  1. Hardin C, Pommier R, Calhoun K, Muller P, Jackson T, et al. (2007) A new harmonal therapy for estrogen receptor negative breast cancer. World J Surg 31: 1041-1046
  2. Park S, Koo JS, Kim MS, Park HS, Lee JS, et al. (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Annals of Oncology 22: 1755-1762.
  3. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, et al. (1984) Androgen receptors in breast cancer. Cancer 54: 2436-2440.
  4. Trivers KF, Lund MJ, Porter PL, LiffElaine JM, Flagg W, et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20: 1071-1082.
  5. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, et al. (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118: 5463-5472.
  6. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. (2000) Prognostic Factors in Breast Cancer. College of American Pathologists Consensus Statement 1999. Arc Pathol Lab Med. 2000; 124 (7):966–978.
  7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25–32. https://doi.org/10.1002/cncr.22381 PMID: 17146782
  8. Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118–145 https://doi.org/10.1200/JCO. 2006.09.2775 PMID: 17159189
  9. Lachapelle J, Foulkes WD (2011) Triple negative and basal like breast cancer implications for Oncologists. Curr Oncol 18: 161-164.
  10. Hanley K, Wang J, Bourne P, Yang Q, Gao AC, et al. (2008) Lack of expression of AR may play a critical role in transformation from in situ to invasive basal subtype of high grade ductal carcinoma of breast. Hum Pathol 39: 386-92.
  11. Hanley K, Wang J, Bourne P, Yang Q, Gao AC, et al. (2008) Lack of expression of AR may play a critical role in transformation from in situ to invasive basal subtype of high grade ductal carcinoma of breast. Hum Pathol 39: 386-392.
  12. Pristauz G, Petru E, Stacher E, Geig JB, Schwarzbrau T, et al. (2010) Androgen receptor expression in breast cancer patients tested for BRCA 1and BRCA 2mutations. Histopathology 57: 877-884.
  13. Secreto G, Toniolo P, Pisani P, Recchione C, Cavalleri A, et al. (1989) Androgens and breast cancer in premenopausal women. Cancer 49: 471-476.
  14. Grattarola R (1964) The premenstrual endometrial pattern of women with breast cancer. A study of progestional activity. Cancer 17 : 1119-1122.
  15. Hickey TE, Robinson JL, Carroll JS, and Tilley WD. Mini review: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012; 26(8):1252–1267. https:// doi.org/10.1210/me.2012-1107 PMID: 22745190.
  16. Birell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia. 1998; 3:95–103. https://doi.org/10.1023/A:1018730519839 PMID: 10819508.
  17. Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, et al. The growth response to androgen receptor signaling in ER-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012; 9:14.
  18. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene.2006; 25:3994–4008. https://doi.org/10.1038/sj.onc.1209415 PMID: 16491124.

Corresponding Author

Dr Debasmita Das

P.G Student, Dept. of pathology, IMS & SUM Hospital

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Cell: 9620814629